Family · Pharmaceutical analytical standards
Miglustat
An iminosugar analogue of glucose, also known as N-butyl-deoxynojirimycin: it inhibits glucosylceramide synthase and so reduces the substance that builds up in Gaucher disease. It was approved in the European Union in 2002 and in the US in 2003. This family brings together the active ingredient, metabolites, labelled standards and other impurities.
Did you know?Before becoming a medicine for rare diseases it attracted interest as an antiviral: in studies it reduced the infectivity of HIV by disrupting the folding of its gp160 glycoprotein.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
